Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment

Table 1 Comparison of drug characteristics between tenofovir amibufenamide and tenofovir alafenamide

	TMF	TAF
Safety	Safe, well-tolerated long-term	Safe, effective, tolerable long-term
Efficacy	Superior long-term efficacy to TAF	Better than TDF, not as good as TMF
Cost-effectiveness	Research data lacking	Cost-effective vs tenofovir, entecavir in wealthier regions
Lipid profiles	Minimal impact on blood lipids, no increased ASCVD risk	May cause dyslipidemia, monitor blood lipids
Special populations	Safe for ages 65+, data lacking for pregnant women, children	Suitable for pregnant women, children aged 12 and older

TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate; ASCVD: Atherosclerotic cardiovascular disease.